Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 3/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.69 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.69 |
| ▸ | CA12 | O43570 | 5/20 | 0.36 |
| ▸ | CA1 | P00915 | 5/20 | 0.36 |
| ▸ | CA2 | P00918 | 5/20 | 0.36 |
| ▸ | CA9 | Q16790 | 5/20 | 0.36 |
| ▸ | COMT | P21964 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.31 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.31 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.31 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.31 |
| ▸ | GRIK5 | Q16478 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19679887 | 0.86 | TYR (0.69) | TYRKDM4EDOHHCA12CA1 | |
| L-Mimosine SCHEMBL11895399 | 0.82 | TYR (1.00) | TYRKDM4EDOHHCA12CA1 | |
| Mimosine SCHEMBL41924 | 0.82 | TYR (1.00) | TYRKDM4EDOHHCA12CA1 | |
| L-Mimosine SCHEMBL41925 | 0.82 | TYR (1.00) | TYRKDM4EDOHHCA12CA1 | |
| Mimosine SCHEMBL9878748 | 0.81 | TYR (0.97) | TYRKDM4EDOHHCA12CA1 | |
| L-Mimosine SCHEMBL1720110 | 0.81 | TYR (0.97) | TYRKDM4EDOHHCA12CA1 | |
| Mimosine SCHEMBL1720107 | 0.81 | TYR (0.97) | TYRKDM4EDOHHCA12CA1 | |
| L-Mimosine SCHEMBL9878752 | 0.79 | TYR (0.73) | TYRKDM4EDOHHCA12CA1 | |
| L-Mimosine SCHEMBL2164631 | 0.79 | TYR (0.94) | TYRKDM4EDOHHCA12CA1 | |
| Mimosine SCHEMBL2164625 | 0.79 | TYR (0.94) | TYRKDM4EDOHHCA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170349548-A1 | P21-ACTIVATED KINASE INHIBITOR | BIOSYSTEM CONSULTING LIMITED COMPANY (JP) | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170349548-A1 | P21-ACTIVATED KINASE INHIBITOR | HIPK1, CDKN1A, HIPK2 | TYR 1687/4885KDM4E 3247/4885DOHH 2061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.